Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities.

瑋俊生物科技有限公司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

EXTENSION OF LONG STOP DATE OF THE SUBSCRIPTION AGREEMENT

References are made to the announcements of Wai Chun Bio-Technology Limited (the "**Company**") dated 14 April 2025 and 15 May 2025 in respect of the connected transaction in relation to the proposed issue of New Convertible Bonds under specific mandate and dated 14 May 2025, 10 June 2025, 25 June 2025, 15 July 2025, 31 July 2025 and 15 August 2025 in relation to the delay in despatch of Circular (the "**Announcements**"). Unless otherwise stated, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

THE SECOND SUPPLEMENTAL AGREEMENT

Pursuant to the terms and conditions of the Subscription Agreement and the supplemental agreement dated 15 May 2025 (the " **First Supplemental Agreement**"), completion of the Subscription Agreement is subject to the conditions precedent being fulfilled or waived (as the case may be) on or before 29 August 2025 (or such other date as may be agreed by the Company and the Existing Bondholder 1), being the Long Stop Date of the Subscription Agreement as amended by the First Supplemental Agreement.

On 20 August 2025 (after trading hours), the Company and the Existing Bondholder 1 has entered into a second supplemental agreement, pursuant to which the parties agreed to extend the Long Stop Date of the Subscription Agreement to 30 September 2025 (or such other date as may be agreed by the Company and the Existing Bondholder 1) as additional time is required for the Company and the Existing Bondholder 1 to procure the fulfillment of the conditions precedent.

Save for the above, all other terms and conditions of the Subscription Agreement shall remain in full force and effect.

Completion of the Subscription, which is subject to the fulfilment of the conditions precedent set out in the Subscription Agreement, may or may not take place. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares and other securities of the Company.

By Order of the Board
Wai Chun Bio-Technology Limited
Lam Ka Chun
Chairman and Chief Executive Officer

Hong Kong, 20 August 2025

As at the date of this announcement, the Board consists of one executive Director, namely Mr. Lam Ka Chun and three independent non-executive Directors, namely Mr. Wong Po Keung, Mr. Wang Ziniu and Ms. Xu Huiling.